Orthocell (OCC) AGM 2025 presentation summary

Strategic vision and growth

• Aims to lead regenerative medicine innovation and target ASX 300 inclusion through disciplined growth and a robust product pipeline.

• Focus on US and Canada launch of Remplir, expansion in Asia, and entry into EU/UK markets.

• Plans to automate manufacturing, invest in people, and implement advanced ERP and BI systems.

• Building a global footprint with collagen medical devices and advancing cell therapy technology.

Commercial performance and financials

• Achieved sixth consecutive quarter of record revenue, reaching $3 million in the September 2025 quarter.

• Strong balance sheet with no debt, no royalties, and approximately $50 million cash at bank.

• Revenue growth not yet reflecting material US Remplir sales, which are expected to ramp up in 2H FY26.

Remplir product launch and US market entry

• Remplir received US FDA 510(k) clearance and entered the $1.6 billion US nerve repair market.

• Over 60 surgeries completed in the US within four months of launch; >100 surgeons engaged.

• Distributor network covers 25 states and 40% of the US population; logistics and inventory in place.

• Value Analysis Committee submissions and state licenses progressing ahead of schedule.